Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European journal of medicinal chemistry

• Publication date

  2010-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2010.08.018PMID 20880612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure of a β1-adrenergic G-protein-coupled receptor

  2008cited by this paper
• The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists.

  2008cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies

  2007cited by this paper
• Distribution of serotonin 5-HT2C receptors in the ventral tegmental area.

  2007cited by this paper
• Editing of the serotonin 2C receptor pre-mRNA: Effects of the Morris Water Maze.

  2007cited by this paper
• Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands*

  2007cited by this paper
• High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor

  2007cited by this paper
• Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.

  2006cited by this paper
• Crystal structure of a photoactivated deprotonated intermediate of rhodopsin

  2006cited by this paper
• A new class of selective, non-basic 5-HT2A receptor antagonists.

  2006cited by this paper
• 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice.

  2006cited by this paper
• Homology modelling of the serotoninergic 5-HT2c receptor

  2006cited by this paper
• On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors

  2006cited by this paper
• Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

  2005cited by this paper
• LigScore: a novel scoring function for predicting binding affinities.

  2005cited by this paper
• Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.

  2005cited by this paper
• Location and nature of the residues important for ligand recognition in G‐protein coupled receptors

  2005cited by this paper
• ZINC - A Free Database of Commercially Available Compounds for Virtual Screening

  2005cited by this paper
• Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs.

  2005cited by this paper
• Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.

  2005cited by this paper
• Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.

  2005cited by this paper
• Novel 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxepin derivatives displaying combined norepinephrine reuptake inhibition and 5-HT2A/2C receptor antagonism.

  2005cited by this paper
• SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.

  2005cited by this paper
• 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.

  2005cited by this paper
• Altered RNA editing of serotonin 2C receptor in a rat model of depression.

  2005cited by this paper
• A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.

  2005cited by this paper
• Essential role for the second extracellular loop in C5a receptor activation

  2005cited by this paper
• Synthesis of potent and selective serotonin 5-HT1B receptor ligands.

  2005cited by this paper
• Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.

  2004cited by this paper
• The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

  2003cited by this paper
• Synthesis and structure-affinity relationship investigations of 5-heteroaryl-substituted analogues of the antipsychotic sertindole. A new class of highly selective alpha(1) adrenoceptor antagonists.

  2003cited by this paper
• Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist.

  2003cited by this paper
• Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.

  2003cited by this paper
• Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors.

  2002cited by this paper
• Serotonin 2C receptor knockout mice: Autoradiographic analysis of multiple serotonin receptors

  2002cited by this paper
• 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists.

  2002cited by this paper
• RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy.

  2001cited by this paper
• RNA Editing of the Human Serotonin 5-HT2C Receptor: Alterations in Suicide and Implications for Serotonergic Pharmacotherapy

  2001cited by this paper
• Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).

  2001cited by this paper
• SB‐272183, a selective 5‐HT1A, 5‐HT1B and 5‐HT1D receptor antagonist in native tissue

  2001cited by this paper
• Synthesis and pharmacological activity of metabolites of the 5-HT(4) receptor antagonist SB-207266.

  2001cited by this paper
• RNA editing of the 5-HT2C receptor is reduced in schizophrenia

  2001cited by this paper
• 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/anxiolytic agents.

  2000cited by this paper
• Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.

  2000cited by this paper
• Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist

  2000cited by this paper
• 2-Aryl tryptamines: selective high-affinity antagonists for the h5-HT2A receptor.

  2000cited by this paper
• Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.

  2000cited by this paper
• Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

  2000cited by this paper
• A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

  2000cited by this paper
• Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

  2000cited by this paper
• Coupling of Canine Serotonin 5‐HT1B and 5‐HT1D Receptor Subtypes to the Formation of Inositol Phosphates by Dual Interactions with Endogenous Gi/o and Recombinant Gα15 Proteins

  2000cited by this paper
• A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism.

  2000cited by this paper
• Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue

  2000cited by this paper
• 1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists.

  2000cited by this paper
• Pharmacophore perception, development, and use in drug design

  2000cited by this paper
• 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

  1999cited by this paper
• RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist

  1999cited by this paper
• A general and fast scoring function for protein-ligand interactions: a simplified potential approach.

  1999cited by this paper
• Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study.

  1999cited by this paper
• Attenuation of haloperidol‐induced catalepsy by a 5‐HT2C receptor antagonist

  1999cited by this paper
• Model studies on a synthetically facile series of N-substituted phenyl-N'-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonists.

  1999cited by this paper
• Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.

  1999cited by this paper
• Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.

  1998cited by this paper
• Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs

  1998cited by this paper
• (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.

  1998cited by this paper
• Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.

  1997cited by this paper
• Development and validation of a genetic algorithm for flexible docking.

  1997cited by this paper
• Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.

  1996cited by this paper
• Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities

  1996cited by this paper
• Functional Reconstitution in Situ of 5-Hydroxytryptamine2c (5HT2c) Receptors with αq and Inverse Agonism of 5HT2c Receptor Antagonists*

  1996cited by this paper
• Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.

  1995cited by this paper
• Evaluation of comparative protein modeling by MODELLER

  1995cited by this paper
• The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure

  1994cited by this paper
• Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines.

  1994cited by this paper
• Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.

  1994cited by this paper
• A single point mutation (Phe340-->Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors.

  1993cited by this paper
• Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.

  1993cited by this paper
• Ritanserin, a Selective 5-HT2/1C Antagonist, and Negative Symptoms in Schizophrenia

  1993cited by this paper
• Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation.

  1989cited by this paper
• The Influence of Ritanserin, a Serotonin Antagonist, in Anxiety Disorders: A Double-blind Placebo-controlled Study versus Lorazepam

  1985cited by this paper
• Inhibition of [3H]spiperone binding to 5-HT2 receptors of rat cerebral cortex by the calcium antagonists verapamil and D600.

  1984cited by this paper
• CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

  1983cited by this paper
• [3H]Mesulergine, a selective ligand for serotonin-2 receptors.

  1983cited by this paper
• Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

  1981cited by this paper
• [3H]Metergoline: A New Ligand of Serotonin Receptors in the Rat Brain

  1981cited by this paper

• Conserved residues in the extracellular loop 2 regulate Stachel-mediated activation of ADGRG2

  2021cites this paper
• Importance of the second extracellular loop for melatonin MT1 receptor function and absence of melatonin binding in GPR50

  2018cites this paper
• A Molecular and Chemical Perspective in Defining Melatonin Receptor Subtype Selectivity

  2013cites this paper
• Structural modelling and dynamics of proteins for insights into drug interactions.

  2012cites this paper
• G-Protein Coupled Receptors: Experimental and Computational Approaches

  2012cites this paper
• Homology Modeling of 5-HT2C Receptors

  2011cites this paper
• Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization.

  2011cites this paper